---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-197957"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:13:05.696301+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acadia R&D Head Elizabeth Thompson plans retirement; stays through 2026 as consultant

## Summary
- Dr. Thompson will retire for personal reasons; remains as Head of R&D until successor appointed, then consultant through end of 2026.
- She will stay through readout of Phase 2 remlifanserin in Alzheimer's disease psychosis and into early Phase 3.
- Company has initiated a search for a new Head of R&D; all ongoing clinical trials continue as planned.
- Thompson joined Acadia in 2024 and helped strengthen clinical capabilities and advance pipeline programs.

## SEC filing metadata
- accession: 0001193125-26-197957
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312526197957/0001193125-26-197957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312526197957/acad-20260427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-197957
- JSON: https://secwatch.observer/filing/0001193125-26-197957.json
- Plain text: https://secwatch.observer/filing/0001193125-26-197957.txt

## Key facts
- Executive change
  Elizabeth H.Z. Thompson retired as Head of Research and Development at ACADIA PHARMACEUTICALS INC.
  - Action: retired
  - Role: Head of Research and Development
  source text: On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the “Company”) of her planned retirement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312526197957/0001193125-26-197957-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.